John H Sampson
Overview
Explore the profile of John H Sampson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
271
Citations
13791
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Westphal M, Levin V, Berger M, Pieper R, Nishikawa R, Bjerkvig R, et al.
J Neurosurg
. 2024 Dec;
142(3):892-898.
PMID: 39705690
No abstract available.
2.
Haskell-Mendoza A, Radhakrishnan S, Nardin A, Eilbacher K, Yang L, Jackson J, et al.
World Neurosurg
. 2023 Sep;
180:e449-e459.
PMID: 37769846
Objective: Preoperative assessment is important for neurosurgical risk stratification, but the level of evidence for individual screening tests is low. In preoperative urinalysis (UA), testing may significantly increase costs and...
3.
Lerner E, Woroniecka K, DAnniballe V, Wilkinson D, Mohan A, Lorrey S, et al.
Nat Cancer
. 2023 Aug;
4(9):1258-1272.
PMID: 37537301
The accepted paradigm for both cellular and anti-tumor immunity relies upon tumor cell killing by CD8 T cells recognizing cognate antigens presented in the context of target cell major histocompatibility...
4.
Carpenter D, Fairchild A, Adamson J, Fecci P, Sampson J, Herndon J, et al.
Adv Radiat Oncol
. 2023 Feb;
8(2):101166.
PMID: 36845614
Purpose: Hypofractionated stereotactic radiosurgery (HF-SRS) with or without surgical resection is potentially a preferred treatment for larger or symptomatic brain metastases (BMs). Herein, we report clinical outcomes and predictive factors...
5.
Swan S, Mehta N, Ilich E, Shen S, Wilkinson D, Anderson A, et al.
Front Immunol
. 2023 Feb;
14:1085547.
PMID: 36817432
Chimeric antigen receptor (CAR) T cell therapy in glioblastoma faces many challenges including insufficient CAR T cell abundance and antigen-negative tumor cells evading targeting. Unfortunately, preclinical studies evaluating CAR T...
6.
Sampson J, Singh Achrol A, Aghi M, Bankiewicz K, Bexon M, Brem S, et al.
Neuro Oncol
. 2023 Jan;
25(6):1085-1097.
PMID: 36640127
Background: MDNA55 is an interleukin 4 receptor (IL4R)-targeting toxin in development for recurrent GBM, a universally fatal disease. IL4R is overexpressed in GBM as well as cells of the tumor...
7.
Tomaszewski W, Waibl-Polania J, Chakraborty M, Perera J, Ratiu J, Miggelbrink A, et al.
Nat Commun
. 2022 Oct;
13(1):6483.
PMID: 36309495
Glioblastoma (GBM) is notorious for its immunosuppressive tumor microenvironment (TME) and is refractory to immune checkpoint blockade (ICB). Here, we identify calmodulin-dependent kinase kinase 2 (CaMKK2) as a driver of...
8.
Wu Y, Wen H, Bernstein Z, Hainline K, Blakney T, Congdon K, et al.
Sci Adv
. 2022 Jul;
8(29):eabm7833.
PMID: 35857833
Subunit vaccines inducing antibodies against tumor-specific antigens have yet to be clinically successful. Here, we use a supramolecular α-helical peptide nanofiber approach to design epitope-specific vaccines raising simultaneous B cell,...
9.
Omuro A, Reardon D, Sampson J, Baehring J, Sahebjam S, Cloughesy T, et al.
Neurooncol Adv
. 2022 Apr;
4(1):vdac025.
PMID: 35402913
Background: The phase 1 cohorts (1c+1d) of CheckMate 143 (NCT02017717) evaluated the safety/tolerability and efficacy of nivolumab plus radiotherapy (RT) ± temozolomide (TMZ) in newly diagnosed glioblastoma. Methods: In total,...
10.
Toro C, Ohnuma T, Komisarow J, Vavilala M, Laskowitz D, James M, et al.
Anesth Analg
. 2022 Feb;
135(6):1245-1252.
PMID: 35203085
Background: Early hypotension after severe traumatic brain injury (sTBI) is associated with increased mortality and poor long-term outcomes. Current guidelines suggest the use of intravenous vasopressors, commonly norepinephrine and phenylephrine,...